{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:27Z","timestamp":1781179107498,"version":"3.54.1"},"reference-count":33,"publisher":"Scientific Scholar","issue":"02","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hand\u2013foot syndrome (HFS) is a distinct and relatively frequent toxic skin reaction associated with certain chemotherapy agents, particularly capecitabine. Given the complications of this syndrome and the critical importance of timely and accurate treatment, the present study aims to investigate the efficacy of topical heparin gel in alleviating HFS in cancer patients undergoing treatment with capecitabine.<\/jats:p>\n                  <jats:p>A total of 40 patients with grade \u2a7d 1 HFS associated with capecitabine were randomly assigned to intervention and control groups. The intervention group received heparin sulfate gel four times a day (21 days) along with capecitabine treatment, while the control group received only capecitabine and placebo gel. The changes in the severity of HFS and clinical manifestations, including erythema, swelling, blisters, hyperkeratosis, and bleeding, at baseline and 3 weeks posttreatment were evaluated. The data were subsequently validated by Fisher's or Chi-square tests.<\/jats:p>\n                  <jats:p>At the beginning of the study, there were no significant differences between the two groups regarding disease manifestations. However, after the intervention, a significant difference was observed between the groups in terms of erythema and swelling (p\u2009=\u20090.001). There were no significant differences between the groups in other manifestations, such as blisters, bleeding, and scaling (p\u2009=\u20090.99). Comparison of the degree of HFS in the intervention group showed that 11 patients experienced improvement after the intervention, while all patients in the control group remained at the same degree of syndrome as before the intervention.<\/jats:p>\n                  <jats:p>The management of HFS in cancer treatment includes a combination of prevention, patient education, symptom improvement, and dose-intensity management. According to the results, it can be said that due to the positive effect of topical heparin gel in improving HFS caused by capecitabine and due to the absence of side effects, the use of topical heparin gel is recommended.<\/jats:p>","DOI":"10.1055\/s-0044-1801832","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T19:08:39Z","timestamp":1737745719000},"page":"186-192","source":"Crossref","is-referenced-by-count":0,"title":["The Effect of Topical Heparin Gel on Reducing Hand\u2013Foot Syndrome Symptoms in Cancer Patients Treated with Capecitabine"],"prefix":"10.25259","volume":"14","author":[{"given":"Maede","family":"Mirjalili","sequence":"additional","affiliation":[{"name":"Department of Internal Surgery Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaser","family":"Salehinajafabadi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Surgery, Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi Raeisi","family":"Shahraki","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Health, Shahrekord University of Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohollah","family":"Masumi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Surgery, Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14740338.2016.1238067","article-title":"Incidence and implications of chemotherapy related hand-foot syndrome","volume":"15","author":"V Nikolaou","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/17588359221086911","article-title":"Topical heparin as an effective and safe treatment for patients with capecitabine-induced hand-foot syndrome: results of a phase IIA trial supported by proteomic profiling of skin biopsies","volume":"14","author":"A Rodr\u00edguez-Garzotto","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"S 01","key":"ref3","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ejon.2004.06.007","article-title":"Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)","volume":"8","author":"Y Lassere","year":"2004","journal-title":"Eur J Oncol Nurs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241228175","article-title":"Incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine-containing chemotherapy regimens","author":"S Abdul Kareem","year":"2024","journal-title":"J Oncol Pharm Pract"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/jamaoncol.2017.1269","article-title":"Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine\u2013induced hand-foot syndrome: a randomized clinical trial","volume":"3","author":"Y-S Yap","year":"2017","journal-title":"JAMA Oncol"},{"issue":"08","key":"ref6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1208\/s12249-020-01862-2","article-title":"Oleosomes encapsulating sildenafil citrate as potential topical nanotherapy for palmar plantar erythrodysesthesia with high ex vivo permeation and deposition","volume":"21","author":"L R Abdelalim","year":"2020","journal-title":"AAPS PharmSciTech"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4143\/crt.2024.080","article-title":"Therapeutic effect of anti-inflammatory tripeptide cream in hand-foot syndrome\/skin reaction related to anticancer drugs: a randomized, double-blind, placebo-controlled pilot trial","volume":"56","author":"Y Yang","year":"2024","journal-title":"Cancer Res Treat"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e20220107","DOI":"10.1590\/1980-220x-reeusp-2023-0107en","article-title":"Topical interventions for preventing hand-foot syndrome resulting from antineoplastic therapy: a scoping review","volume":"57","author":"F C Gialaim Purcino Dos Reis","year":"2023","journal-title":"Rev Esc Enferm USP"},{"issue":"12","key":"ref9","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1002\/ijc.31269","article-title":"Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome","volume":"142","author":"X Z Huang","year":"2018","journal-title":"Int J Cancer"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"E149","DOI":"10.1188\/20.ONF.E149-E160","article-title":"Targeted therapy\u2013and chemotherapy-associated skin toxicities: systematic review and meta-analysis","volume":"47","author":"J Ding","year":"2020","journal-title":"Oncol Nurs Forum"},{"issue":"04","key":"ref11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","article-title":"Multikinase inhibitor-induced hand\u2013foot skin reaction: a review of clinical presentation, pathogenesis, and management","volume":"17","author":"K Chanprapaph","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"K K Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"05","key":"ref13","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1093\/oncolo\/oyab067","article-title":"Safety and efficacy of bis-glyceryl ascorbate as prophylaxis for hand-foot skin reaction: a single-arm, open-label phase i\/ii study (DGA study)","volume":"27","author":"K Yamamoto","year":"2022","journal-title":"Oncologist"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"101866","DOI":"10.1016\/j.ejon.2020.101866","article-title":"A pilot randomized double-blind, placebo-controlled study on the effects of the topical application of pyridoxine on palmar-plantar erythrodysesthesia (PPE) induced by capecitabine or pegylated liposomal doxorubicin (PLD)","volume":"50","author":"A Charalambous","year":"2021","journal-title":"Eur J Oncol Nurs"},{"issue":"02","key":"ref15","first-page":"5","article-title":"Hand-foot syndrome in cancer patients: concepts, assessment and management of symptoms","volume":"35","author":"R Sanches","year":"2015","journal-title":"Applied Cancer Research."},{"issue":"02","key":"ref16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/annonc\/mdt541","article-title":"A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma","volume":"25","author":"N Shinohara","year":"2014","journal-title":"Ann Oncol"},{"issue":"11","key":"ref17","first-page":"1574","article-title":"Hand-foot syndrome with tyrosine kinase inhibitor therapy: treatment recommendations [in German]","volume":"52","author":"G Burbach","year":"2013","journal-title":"Urologe A"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3816\/SCT.2004.n.013","article-title":"Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome: etiology and emerging therapies","volume":"1","author":"A S Clark","year":"2004","journal-title":"Support Cancer Ther"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1634\/theoncologist.2011-0115","article-title":"Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer","volume":"16","author":"P Gomez","year":"2011","journal-title":"Oncologist"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/JLB.3RU0618-246R","article-title":"Heparan sulfate as a regulator of inflammation and immunity","volume":"105","author":"L E Collins","year":"2019","journal-title":"J Leukoc Biol"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1096\/fj.02-0739rev","article-title":"Syndecans in inflammation","volume":"17","author":"M G\u00f6tte","year":"2003","journal-title":"FASEB J"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1055\/s-0040-1715460","article-title":"The anticoagulant and nonanticoagulant properties of heparin","volume":"120","author":"D MH Beurskens","year":"2020","journal-title":"Thromb Haemost"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"104027","DOI":"10.1016\/j.mvr.2020.104027","article-title":"The applications of heparin in vascular tissue engineering","volume":"131","author":"S Aslani","year":"2020","journal-title":"Microvasc Res"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1021\/bi9821317","article-title":"Heparin is essential for a single keratinocyte growth factor molecule to bind and form a complex with two molecules of the extracellular domain of its receptor","volume":"38","author":"Y R Hsu","year":"1999","journal-title":"Biochemistry"},{"issue":"10","key":"ref25","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/jcph.516","article-title":"Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin","volume":"55","author":"B B Yang","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"01","key":"ref26","first-page":"442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"J JM Kwakman","year":"2020","journal-title":"Oncol Rev"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/ced.14486","article-title":"Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis","volume":"46","author":"S Lian","year":"2021","journal-title":"Clin Exp Dermatol"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"e038276","DOI":"10.1136\/bmjopen-2020-038276","article-title":"Hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study","volume":"10","author":"S Zenda","year":"2020","journal-title":"BMJ Open"},{"issue":"22","key":"ref29","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","article-title":"Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO quality of life working group","volume":"33","author":"R-D Hofheinz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3892\/ol.2013.1706","article-title":"Treatment of capecitabine-induced hand-foot syndrome using a topical retinoid: a case report","volume":"7","author":"M Inokuchi","year":"2014","journal-title":"Oncol Lett"},{"issue":"535","key":"ref31","first-page":"824","article-title":"The effect of captopril added to standard chemotherapy regimen containing capecitabine in the prevention of hand and foot syndrome in patients with colorectal cancer","volume":"37","author":"M Roayaei","year":"2019","journal-title":"Majallah-i Danishkadah-i Pizishki-i Isfahan"},{"issue":"07","key":"ref32","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00210-022-02339-8","article-title":"Pharmaceutical and clinical studies of celecoxib topical hydrogel for management of chemotherapy-induced hand-foot syndrome","volume":"396","author":"D Shayeganmehr","year":"2023","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"03","key":"ref33","first-page":"907","article-title":"Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions","volume":"21","author":"J R Li","year":"2013","journal-title":"Support Care Cancer"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1801832.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:13:08Z","timestamp":1781176388000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/the-effect-of-topical-heparin-gel-on-reducing-hand-foot-syndrome-symptoms-in-cancer-patients-treated-with-capecitabine\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":33,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2025,12,18]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1801832","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}